PFIZER INC.

Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.

Radiance Biopharma has signed an exclusive licensing agreement with Novatim for RB-601™, a first-in-class bispecific nanobody ADC targeting c-MET and EGFR receptors.

Biohaven's Vyglxia could become the first approved treatment for spinocerebellar ataxia, a rare genetic brain disorder affecting movement and coordination, with FDA decision expected between October and December.

Olema Oncology and Pfizer have announced a new clinical trial collaboration to evaluate the combination of palazestrant and atirmociclib in approximately 35 patients with ER+/HER2- metastatic breast cancer.

The FDA approved Pfizer-BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine on August 27 for adults 65 and older and individuals aged 5-64 with high-risk conditions.

ACROBiosystems and DAAN Biotherapeutics signed a strategic MOU to establish a multi-faceted collaboration framework for developing precision immunotherapies targeting drug-resistant cancers.

Eli Lilly's Verzenio plus endocrine therapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone in patients with HR+, HER2-, node-positive, high-risk early breast cancer.

Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.

Bristol Myers Squibb will present new clinical and real-world data for Camzyos (mavacamten) and Eliquis (apixaban) at the European Society of Cardiology Congress 2025 in Madrid.

The global influenza pipeline has expanded to include 120+ companies developing 120+ treatment therapies, with breakthrough innovations spanning vaccines, antibodies, and combination therapies.